Literature DB >> 7905495

Cells of Th2 cytokine phenotype prevent LPS-induced lethality during murine graft-versus-host reaction. Regulation of cytokines and CD8+ lymphoid engraftment.

D H Fowler1, K Kurasawa, A Husebekk, P A Cohen, R E Gress.   

Abstract

A murine parent-into-F1 graft-vs-host reaction (GVHR) model that utilizes LPS to induce lethality was used to evaluate the in vivo regulatory role of donor cells of Th2 cytokine phenotype. Transfer of B6 spleen cells into B6C3F1 hosts was lethal when LPS endotoxin (15 micrograms) was administered on day 7 after cell transfer. Parental cells of Th2 cytokine phenotype were generated by treating B6 mice in vivo with a combination of IL-2 and IL-4 or with high dose IL-2. The CD4-enriched population from these cytokine-treated mice expressed and secreted increased levels of IL-4 and IL-10, with concomitantly decreased IL-2 and IFN-gamma. Cell mixing experiments (parental spleen cells+parental CD4-enriched. Th2-type cells) demonstrated that the Th2-type cells protected F1 hosts from LPS-induced lethality. These mice were analyzed to study possible mechanisms by which this protection was mediated. Compared with mice undergoing LPS-induced lethality during GVHR, Th2-protected mice had: 1) lower levels of donor CD8+ lymphoid engraftment, 2) in vivo suppression of IFN-gamma mRNA, 3) in vivo augmentation of IL-4 mRNA, and 4) a reduction in serum TNF-alpha. We thus conclude that donor cells of Th2 cytokine phenotype prevent LPS-induced, TNF-alpha-mediated lethality during GVHR, and that this protection is associated with regulation of both cellular- and cytokine-mediated events. As a result, we propose that cells of Th2 cytokine phenotype may represent a novel approach for establishing allogeneic lymphoid engraftment without lethal graft-vs-host disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7905495

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  29 in total

1.  Blocking IL-21 signaling ameliorates xenogeneic GVHD induced by human lymphocytes.

Authors:  Keli L Hippen; Christoph Bucher; Dawn K Schirm; Amanda M Bearl; Ty Brender; Kathy A Mink; Kimberly S Waggie; Regis Peffault de Latour; Anne Janin; Julie M Curtsinger; Stacey R Dillon; Jeffrey S Miller; Gerard Socie; Bruce R Blazar
Journal:  Blood       Date:  2011-11-10       Impact factor: 22.113

2.  Rapamycin generates anti-apoptotic human Th1/Tc1 cells via autophagy for induction of xenogeneic GVHD.

Authors:  Shoba Amarnath; Francis A Flomerfelt; Carliann M Costanzo; Jason E Foley; Jacopo Mariotti; Daniel M Konecki; Anu Gangopadhyay; Michael Eckhaus; Susan Wong; Bruce L Levine; Carl H June; Daniel H Fowler
Journal:  Autophagy       Date:  2010-05-16       Impact factor: 16.016

Review 3.  NKT cells, Treg, and their interactions in bone marrow transplantation.

Authors:  Holbrook E Kohrt; Asha B Pillai; Robert Lowsky; Samuel Strober
Journal:  Eur J Immunol       Date:  2010-07       Impact factor: 5.532

Review 4.  Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new.

Authors:  James M Coghill; Stefanie Sarantopoulos; Timothy P Moran; William J Murphy; Bruce R Blazar; Jonathan S Serody
Journal:  Blood       Date:  2011-01-18       Impact factor: 22.113

5.  Prevention of GVHD while sparing GVL effect by targeting Th1 and Th17 transcription factor T-bet and RORγt in mice.

Authors:  Yu Yu; Dapeng Wang; Chen Liu; Kane Kaosaard; Kenrick Semple; Claudio Anasetti; Xue-Zhong Yu
Journal:  Blood       Date:  2011-08-19       Impact factor: 22.113

6.  Murine graft-versus-host disease induced using interferon-gamma-deficient grafts features antibodies to double-stranded DNA, T helper 2-type cytokines and hypereosinophilia.

Authors:  Cynthia A Ellison; David S Bradley; Jacqie M M Fischer; Kent T Hayglass; John G Gartner
Journal:  Immunology       Date:  2002-01       Impact factor: 7.397

7.  LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation.

Authors:  K R Cooke; A Gerbitz; J M Crawford; T Teshima; G R Hill; A Tesolin; D P Rossignol; J L Ferrara
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

8.  Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo.

Authors:  Andreas A Erdmann; Zhan-Guo Gao; Unsu Jung; Jason Foley; Todd Borenstein; Kenneth A Jacobson; Daniel H Fowler
Journal:  Blood       Date:  2005-03-03       Impact factor: 22.113

Review 9.  Antibiotic-mediated modification of the intestinal microbiome in allogeneic hematopoietic stem cell transplantation.

Authors:  J Whangbo; J Ritz; A Bhatt
Journal:  Bone Marrow Transplant       Date:  2016-08-15       Impact factor: 5.483

10.  Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity.

Authors:  Robert Zeiser; Sawsan Youssef; Jeanette Baker; Neeraja Kambham; Lawrence Steinman; Robert S Negrin
Journal:  Blood       Date:  2007-09-07       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.